MicroRNAs in congenital heart disease

Annals of Translational Medicine

Volumn 3, Issue 21, 2015, Pages

  Smith, Tanya ^a,b   Rajakaruna, Cha ^b   Caputo, Massimo ^a,b   Emanueli, Costanza ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Biomarkers; Congenital heart disease (CHD); Heart development; MicroRNAs (miRs)

Indexed keywords

EID: 85015490983     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.12.25     Document Type: Review

References (93)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
3. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 2015;11:23-33.
4. Simpson LJ, Ansel KM. MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest 2015;125:2242-9.
5. Chen J. Signaling pathways in HPV-associated cancers and therapeutic implications. Rev Med Virol 2015;25:1:24-53
6. Cai B, Pan Z, Lu Y. The roles of microRNAs in heart diseases: a novel important regulator. Curr Med Chem 2010;17:407-11.
7. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44.
8. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007;129:303-17.
9. Catalucci D, Latronico MV, Condorelli G. MicroRNAs control gene expression: importance for cardiac development and pathophysiology. Ann N Y Acad Sci 2008;1123:20-9.
10. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008;79:562-70.
11. Chen J, Wang DZ. microRNAs in cardiovascular development. J Mol Cell Cardiol 2012;52:949-57.
12. Yu ZB, Han SP, Bai YF, et al. MicroRNA expression profiling in fetal single ventricle malformation identified by deep sequencing. Int J Mol Med 2012;29:53-60.
13. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71.
14. Meberg A, Lindberg H, Thaulow E. Congenital heart defects: the patients who die. Acta Paediatr 2005;94:1060-5.
15. Trojnarska O, Grajek S, Katarzynski S, et al. Predictors of mortality in adult patients with congenital heart disease. Cardiol J 2009;16:341-7.
16. Campbell M. Incidence of cardiac malformations at birth and later, and neonatal mortality. Br Heart J 1973;35:189-200.
17. van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 2011;58:2241-7.
18. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005;26:2325-33.
19. EUROCAT Special Report on Congenital Heart Defects. EUROCAT Central Registry, University of Ulster. Available online: http://www.eurocat-network.eu/content/Special-Report-CHD.pdf. Accessed November 03, 2015.
20. Tubman TR, Shields MD, Craig BG, et al. Congenital heart disease in Down's syndrome: two year prospective early screening study. BMJ 1991;302:1425-7.
21. Gama-Carvalho M, Andrade J, Brás-Rosário L. Regulation of Cardiac Cell Fate by microRNAs: Implications for Heart Regeneration. Cells 2014;3:996-1026.
22. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004;10:1957-66
23. Rodriguez A, Griffiths-Jones S, Ashurst JL, et al. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902-10.
24. Kuehbacher A, Urbich C, Zeiher AM, et al. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007;101:59-68.
25. Suárez Y, Fernández-Hernando C, Pober JS, et al. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007;100:1164-73.
26. Suárez Y, Fernández-Hernando C, Yu J, et al. Dicerdependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A 2008;105:14082-7.
27. Yang WJ, Yang DD, Na S, et al. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 2005;280:9330-5.
28. Shilo S, Roy S, Khanna S, Sen CK. Evidence for the involvement of miRNA in redox regulated angiogenic response of human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:471-7.
29. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008;105:2111-6.
30. da Costa Martins PA, Bourajjaj M, Gladka M, et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008;118:1567-76.
31. Suárez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res 2009;104:442-54.
32. Emanueli C, Shearn AI, Angelini GD, et al. Exosomes and exosomal miRNAs in cardiovascular protection and repair. Vascul Pharmacol 2015;71:24-30.
33. Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995;16:103-13.
34. Liu N, Williams AH, Kim Y, et al. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A 2007;104:20844-9.
35. Li J, Cao Y, Ma XJ, et al. Roles of miR-1-1 and miR-181c in ventricular septal defects. Int J Cardiol 2013;168:1441-6.
36. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132:875-86.
37. Zhu S, Cao L, Zhu J, et al. Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects. Clin Chim Acta 2013;424:66-72.
38. Li D, Ji L, Liu L, et al. Characterization of circulating microRNA expression in patients with a ventricular septal defect. PLoS One 2014;9:e106318.
39. Goddeeris MM, Rho S, Petiet A, et al. Intracardiac septation requires hedgehog-dependent cellular contributions from outside the heart. Development 2008;135:1887-95.
40. Latronico MV, Catalucci D, Condorelli G. MicroRNA and cardiac pathologies. Physiol Genomics 2008;34:239-42.
41. O'Brien JE Jr, Kibiryeva N, Zhou XG, et al. Noncoding RNA expression in myocardium from infants with tetralogy of Fallot. Circ Cardiovasc Genet 2012;5:279-86.
42. Nigam V, Sievers HH, Jensen BC, et al. Altered Micrornas in Bicuspid Aortic Valve: A Comparison between Stenotic and Insufficient Valves. J Heart Valve Dis 2010;19:459-65.
43. Yanagawa B, Lovren F, Pan Y, et al. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. J Thorac Cardiovasc Surg 2012;144:256-62.
44. Waight DJ, Bacha EA, Kahana M, et al. Catheter therapy of Swiss cheese ventricular septal defects using the Amplatzer muscular VSD occluder. Catheter Cardiovasc Interv 2002;55:355-61.
45. Anderson RH, Brown NA, Mohun TJ. Insights regarding the normal and abnormal formation of the atrial and ventricular septal structures. Clin Anat 2015. [Epub ahead of print].
46. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005;436:214-20.
47. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22:3242-54.
48. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116:258-67.
49. Torfs CP, Christianson RE. Anomalies in Down syndrome individuals in a large population-based registry. Am J Med Genet 1998;77:431-8.
50. Frid C, Drott P, Lundell B, et al. Mortality in Down's syndrome in relation to congenital malformations. J Intellect Disabil Res 1999;43:234-41.
51. Han J, Lee Y, Yeom KH, et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004;18:3016-27.
52. Omran A, Elimam D, Webster KA, et al. MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle. Cardiol Young 2013;23:642-55.
53. Roberts A, Allanson J, Jadico SK, et al. The cardiofaciocutaneous syndrome. J Med Genet 2006;43:833-42.
54. Perez E, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge and velocardiofacial syndromes). Curr Opin Pediatr 2002;14:678-83.
55. Huang ZP, Chen JF, Regan JN, et al. Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects. Arterioscler Thromb Vasc Biol 2010;30:2575-86.
56. Veldtman GR, Connolly HM, Grogan M, et al. Outcomes of pregnancy in women with tetralogy of Fallot. J Am Coll Cardiol 2004;44:174-80.
57. Burn J, Brennan P, Little J, et al. Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. Lancet 1998;351:311-6.
58. Zellers TM, Driscoll DJ, Michels VV. Prevalence of significant congenital heart defects in children of parents with Fallot's tetralogy. Am J Cardiol 1990;65:523-6.
59. Anderson RH, Baker EJ, Macartney FJ, et al. editors. Paediatric cardiology, 2nd edition. London: Churchill Livingstone, 2002;1213-502.
60. Goldmuntz E, Clark BJ, Mitchell LE, et al. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 1998;32:492-8.
61. Bittel DC, Kibiryeva N, Marshall JA, et al. MicroRNA-421 Dysregulation is Associated with Tetralogy of Fallot. Cells 2014;3:713-23.
62. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005;111:3316-26.
63. Sanford LP, Ormsby I, Gittenberger-de Groot AC, et al. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 1997;124:2659-70.
64. Bartram U, Molin DG, Wisse LJ, et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 2001;103:2745-52.
65. Jiao K, Langworthy M, Batts L, et al. Tgfbeta signaling is required for atrioventricular cushion mesenchyme remodeling during in vivo cardiac development. Development 2006;133:4585-93.
66. Sridurongrit S, Larsson J, Schwartz R, et al. Signaling via the Tgf-beta type I receptor Alk5 in heart development. Dev Biol 2008;322:208-18.
67. Charng MJ, Frenkel PA, Lin Q, et al. A constitutive mutation of ALK5 disrupts cardiac looping and morphogenesis in mice. Dev Biol 1998;199:72-9.
68. Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet 2007;15:724-33.
69. Mizuguchi T, Matsumoto N. Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J Hum Genet 2007;52:1-12.
70. Akutsu K, Morisaki H, Takeshita S, et al. Phenotypic heterogeneity of Marfan-like connective tissue disorders associated with mutations in the transforming growth factor-beta receptor genes. Circ J 2007;71:1305-9.
71. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275-81.
72. van de Laar IM, Oldenburg RA, Pals G, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011;43:121-6.
73. Lindsay ME, Schepers D, Bolar NA, et al. Loss-offunction mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet 2012;44:922-7.
74. Boileau C, Guo DC, Hanna N, et al. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet 2012;44:916-21.
75. Peng Y, Song L, Zhao M, et al. Critical roles of miRNAmediated regulation of TGFβ signalling during mouse cardiogenesis. Cardiovasc Res 2014;103:258-67.
76. Saxena A, Tabin CJ. miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. Proc Natl Acad Sci U S A 2010;107:87-91.
77. Chen JF, Murchison EP, Tang R, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008;105:2111-6.
78. Sussman MA, Völkers M, Fischer K, et al. Myocardial AKT: the omnipresent nexus. Physiol Rev 2011;91:1023-70.
79. Rajan KS, Velmurugan G, Pandi G, et al. miRNA and piRNA mediated Akt pathway in heart: antisense expands to survive. Int J Biochem Cell Biol 2014;55:153-6.
80. Pillai VB, Sundaresan NR, Gupta MP. Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ Res 2014;114:368-78.
81. Liu J, van Mil A, Vrijsen K, et al. MiR-155 targets RIP1 and thus prevents necrotic cell death of human cardiomyocyte progenitor cells. J Cell Mol Med 2011;15:1474-82.
82. Chen J, Zhang XD, Proud C. Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 doubleknockout mice. Sci Signal 2015;8:pe1.
83. Jin Y, Chauhan SK, El Annan J, et al. A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol 2011;178:1922-9.
84. Zhou M, Cai J, Tang Y, et al. MiR-17-92 cluster is a novel regulatory gene of cardiac ischemic/reperfusion injury. Med Hypotheses 2013;81:108-10.
85. Yu QQ, Wu H, Huang X, et al. MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomed Pharmacother 2014;68:155-61.
86. Chen T, Ding G, Jin Z, et al. Insulin ameliorates miR-1-induced injury in H9c2 cells under oxidative stress via Akt activation. Mol Cell Biochem 2012;369:167-74.
87. Liu B, Wu X, Liu B, et al. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta 2012;1822:1692-704.
88. Guo P, Nie Q, Lan J, et al. C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem Biophys Res Commun 2013;441:186-90.
89. Xu XD, Song XW, Li Q, et al. Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy. J Cell Physiol 2012;227:1391-8.
90. Nigam V, Sievers HH, Jensen BC, et al. Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis 2010;19:459-65.
91. Cheng Y, Tan N, Yang J, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010;119:87-95.
92. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011;39:7223-33.
93. Xing HJ, Li YJ, Ma QM, et al. Identification of microRNAs present in congenital heart disease associated copy number variants. Eur Rev Med Pharmacol Sci 2013;17:2114-20.